Healthcare entity
regulation is the sole category represented across all 1 tracked stories. OST-HER2 is most often covered alongside Center for Biologics Evaluation and Research, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention OST-HER2, all published on August 14, 2026.
Last mentioned: Aug 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. OST-HER2 is most often covered alongside Center for Biologics Evaluation and Research, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention OST-HER2, all published on August 14, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering OST-HER2. Shared-story counts are live from our verified record — not editorial picks.
Interim 3-year overall survival data expected
Company expects to announce interim 3-year overall survival data from the Phase 2b OST-HER2 trial in early September 2026.
FDA Type C Statistical Methods Meeting
Meeting expected in mid-September 2026 with CBER to review statistical methods, comparator appropriateness, RMAT designation, and rolling review.
MHRA Scientific Advice Meeting
UK MHRA meeting expected in September 2026 to review statistical methods supporting the CMAA, including finalization with 2.5-year overall survival.
Company announces FDA Type C meeting and MHRA parallel review
OS Therapies announces FDA granted Type C Statistical Methods Meeting to review 2.5-year OS data for OST-HER2; MHRA Scientific Advice Meeting granted in parallel.
For healthcare regulators and health systems, OS Therapies' FDA Type C meeting on OST-HER2 will test whether historical control data can support approval in rare osteosarcoma. With MHRA running parallel advice and a biomarker qualification review pending, the case could reshape evidence standards in ultra-rare cancers.
OST-HER2 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
